Dactinomycin is an old drug with activity in some childhood cancers; it acts as an inhibitor of RNA polymerase I. Its activity in acute myeloid leukemia has not been thoroughly examined. However, it has induced remissions in some patients with treatment-refractory disease.
No takes yet. Share an insight, caveat, or question.
Falini et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: